FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx today announced the launch of their GPCR profiling services utilizing their PathHunter™ ß-arrestin technology platform. The profiling panel includes a growing list of GPCRs representing 32 ligand families. All GPCR expressing cell lines are based on the revolutionary PathHunter™ Arrestin technology which measures GPCR activation without the need of target over-expression, force coupling, imaging or second messenger detection. The robust PathHunter™ platform is ideal for determining cross-reactivity, dose response, agonist/antagonist activity, SAR and allosteric modulation of lead compounds. DiscoveRx is the only commercial alternative for cell based GPCR screening and profiling without the need of force coupling. The PathHunter™ technology provides competitive binding assay pharmacology in a cell based assay platform.
